메뉴 건너뛰기




Volumn 2, Issue 1, 1999, Pages 89-92

New Medical Treatment for Acromegaly

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HORMONE ANTAGONIST; SOMATOSTATIN;

EID: 0033140118     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009930223314     Document Type: Article
Times cited : (7)

References (38)
  • 1
    • 0029111738 scopus 로고
    • Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
    • Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995;80: 2768-2775.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 2768-2775
    • Newman, C.B.1    Melmed, S.2    Snyder, P.J.3
  • 3
    • 0029786520 scopus 로고    scopus 로고
    • Acromegaly
    • Melmed S. Acromegaly. Metabolism 1996;45:51-52.
    • (1996) Metabolism , vol.45 , pp. 51-52
    • Melmed, S.1
  • 4
    • 0029832211 scopus 로고    scopus 로고
    • Treatment options for acromegaly
    • Sheppard MC, Stewart PM. Treatment options for acromegaly. Metabolism 1996;45:63-64.
    • (1996) Metabolism , vol.45 , pp. 63-64
    • Sheppard, M.C.1    Stewart, P.M.2
  • 5
    • 0029810971 scopus 로고    scopus 로고
    • The role of somatostatin agonistic analogs in the treatment of acromegaly
    • Tolis G. The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism 1996;45:109-110.
    • (1996) Metabolism , vol.45 , pp. 109-110
    • Tolis, G.1
  • 6
    • 0030668649 scopus 로고    scopus 로고
    • A risk-benefit assessment of octreotide in the treatment of acromegaly
    • van der Lely AJ, de HW, Lamberts SW A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Saf 1997;17:317-324.
    • (1997) Drug Saf , vol.17 , pp. 317-324
    • Van Der Lely, A.J.1    De, H.W.2    Lamberts, S.W.3
  • 7
    • 0025783499 scopus 로고
    • Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group
    • Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-1578.
    • (1991) Arch Intern Med , vol.151 , pp. 1573-1578
    • Vance, M.L.1    Harris, A.G.2
  • 8
    • 0031022831 scopus 로고    scopus 로고
    • Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
    • Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 18-22
    • Caron, P.1    Morange-Ramos, I.2    Cogne, M.3    Jaquet, P.4
  • 9
    • 0028828426 scopus 로고
    • Sandostatin LAR in acromegalic patients: A dose-range study
    • Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-3607.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 3601-3607
    • Flogstad, A.K.1    Halse, J.2    Haldorsen, T.3
  • 10
    • 0028286788 scopus 로고
    • Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
    • Marek J, Hana V, Krsek M, et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-26.
    • (1994) Eur J Endocrinol , vol.131 , pp. 20-26
    • Marek, J.1    Hana, V.2    Krsek, M.3
  • 11
    • 0028222326 scopus 로고
    • Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
    • Morange I, De Boisvillers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79:145-151.
    • (1994) J Clin Endocrinol Metab , vol.79 , pp. 145-151
    • Morange, I.1    De Boisvillers, F.2    Chanson, P.3
  • 12
    • 0031036540 scopus 로고    scopus 로고
    • Depot somatostatin analogs - A new first line therapy for acromegaly
    • Robbins RJ. Depot somatostatin analogs - a new first line therapy for acromegaly. J Clin Endocrinol Metab 1997; 82:15-17.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 15-17
    • Robbins, R.J.1
  • 13
    • 0028864383 scopus 로고
    • Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
    • Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80: 3267-3272.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 3267-3272
    • Stewart, P.M.1    Kane, K.F.2    Stewart, S.E.3
  • 14
    • 0031930952 scopus 로고    scopus 로고
    • Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
    • Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998; 48:311-316.
    • (1998) Clin Endocrinol (Oxf) , vol.48 , pp. 311-316
    • Davies, P.H.1    Stewart, S.E.2    Lancranjan, L.3
  • 15
    • 0031023098 scopus 로고    scopus 로고
    • Sandostatin LAR in acromegalic patients: Long-term treatment
    • Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: Long-term treatment. J Clin Endocrinol Metab 1997;82:23-28.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 23-28
    • Flogstad, A.K.1    Halse, J.2    Bakke, S.3
  • 16
    • 0030853659 scopus 로고    scopus 로고
    • Acromegaly and its treatment
    • discussion S67-71:S49-S51
    • Lamberts SW. Acromegaly and its treatment. J Endocrinol 1997;155(Suppl 1):S49-51; discussion S67-71:S49-S51.
    • (1997) J Endocrinol , vol.155 , Issue.1 SUPPL.
    • Lamberts, S.W.1
  • 17
    • 0025190143 scopus 로고
    • Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety
    • Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med 1990;112:173-181.
    • (1990) Ann Intern Med , vol.112 , pp. 173-181
    • Ho, K.Y.1    Weissberger, A.J.2    Marbach, P.3    Lazarus, L.4
  • 18
    • 0031028364 scopus 로고    scopus 로고
    • Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
    • Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99:789-798.
    • (1997) J Clin Invest , vol.99 , pp. 789-798
    • Shimon, I.1    Taylor, J.E.2    Dong, J.Z.3
  • 19
    • 0030850528 scopus 로고    scopus 로고
    • Structure and function of somatostatin receptors in growth hormone control
    • discussion S7-8:S3-S6
    • Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997;155(Suppl 1):S3-6; discussion S7-8:S3-S6.
    • (1997) J Endocrinol , vol.155 , Issue.1 SUPPL.
    • Shimon, I.1    Melmed, S.2
  • 20
    • 0030690974 scopus 로고    scopus 로고
    • Somatostatin receptor (SSTR) subtype- selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
    • Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype- selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100:2386-2392.
    • (1997) J Clin Invest , vol.100 , pp. 2386-2392
    • Shimon, I.1    Yan, X.2    Taylor, J.E.3
  • 21
    • 2342516114 scopus 로고    scopus 로고
    • Effect of two somatostatin analogs with different selectivity for sub-type 2 and 5 of the somatostatin receptor on growth hormone (GH) secretion in human GH-secreting adenomas cultured in vitro
    • June 24-27, New Orleans, Louisiana, USA [P2-212]
    • Giustina A, Bonfanti C, Bollati A, et al. Effect of two somatostatin analogs with different selectivity for sub-type 2 and 5 of the somatostatin receptor on growth hormone (GH) secretion in human GH-secreting adenomas cultured in vitro. The 80th Annual Meeting of the Endocrine Society, 1998 June 24-27, New Orleans, Louisiana, USA [P2-212].
    • (1998) The 80th Annual Meeting of the Endocrine Society
    • Giustina, A.1    Bonfanti, C.2    Bollati, A.3
  • 22
    • 0030993137 scopus 로고    scopus 로고
    • Combined cabegoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency
    • Cesario F, Borretta G, Meineri I, et al. Combined cabegoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency. J Pediatr Endocrinol Metab 1997;10:231-236.
    • (1997) J Pediatr Endocrinol Metab , vol.10 , pp. 231-236
    • Cesario, F.1    Borretta, G.2    Meineri, I.3
  • 23
    • 0030790217 scopus 로고    scopus 로고
    • Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy
    • Colao A, Lombardi G. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. J Clin Endocrinol Metab 1997;82:2756.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 2756
    • Colao, A.1    Lombardi, G.2
  • 24
    • 0030807953 scopus 로고    scopus 로고
    • Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy
    • Delgrange E, Donckier J. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. J CLIn Endocrinol Metab 1997;82:2755-2756.
    • (1997) J CLIn Endocrinol Metab , vol.82 , pp. 2755-2756
    • Delgrange, E.1    Donckier, J.2
  • 25
    • 8244250765 scopus 로고    scopus 로고
    • Treatment of macroprolactinoma with cabergoline: A study of 85 patients
    • Ferrari Cl, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409-413.
    • (1997) Clin Endocrinol (Oxf) , vol.46 , pp. 409-413
    • Ferrari, Cl.1    Abs, R.2    Bevan, J.S.3
  • 26
    • 0026497610 scopus 로고
    • Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group
    • Webster J, Piscitelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) 1992;37:534-541.
    • (1992) Clin Endocrinol (Oxf) , vol.37 , pp. 534-541
    • Webster, J.1    Piscitelli, G.2    Polli, A.3
  • 27
    • 0027247927 scopus 로고
    • The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group
    • Webster J, Piscitelli G, Polli A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf) 1993;39:323-329.
    • (1993) Clin Endocrinol (Oxf) , vol.39 , pp. 323-329
    • Webster, J.1    Piscitelli, G.2    Polli, A.3
  • 28
    • 0026516108 scopus 로고
    • Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
    • Brue T, Pellegrini I, Gunz G, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endorinol Metab 1992;74: 577-584.
    • (1992) J Clin Endorinol Metab , vol.74 , pp. 577-584
    • Brue, T.1    Pellegrini, I.2    Gunz, G.3
  • 29
  • 30
    • 0027215263 scopus 로고
    • Long-term treatment of macroprolactinomas with CV 205-502
    • Kvistborg A, Halse J, Bakke S, et al. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh) 1993;128:301-307.
    • (1993) Acta Endocrinol (Copenh) , vol.128 , pp. 301-307
    • Kvistborg, A.1    Halse, J.2    Bakke, S.3
  • 31
    • 0023154459 scopus 로고
    • CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion
    • Rasmussen C, Bergh T, Wide L, Brownell J. CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 1987;26:321-326.
    • (1987) Clin Endocrinol (Oxf) , vol.26 , pp. 321-326
    • Rasmussen, C.1    Bergh, T.2    Wide, L.3    Brownell, J.4
  • 32
    • 0025728631 scopus 로고
    • The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine
    • van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72:1136-1141.
    • (1991) J Clin Endocrinol Metab , vol.72 , pp. 1136-1141
    • Van Der Lely, A.J.1    Brownell, J.2    Lamberts, S.W.3
  • 34
    • 0031792509 scopus 로고    scopus 로고
    • Cabergoline in the treatment of acromegaly: A study in 64 patients
    • Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
    • (1998) J Clin Endocrinol Metab , vol.83 , pp. 374-378
    • Abs, R.1    Verhelst, J.2    Maiter, D.3
  • 35
    • 0031026529 scopus 로고    scopus 로고
    • Effect of different dopaminergic agents in the treatment of acromegaly
    • Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 518-523
    • Colao, A.1    Ferone, D.2    Marzullo, P.3
  • 36
    • 0030774607 scopus 로고    scopus 로고
    • Evidence for dopamine agonists in the treatment of acromegaly
    • Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 1997;155(Suppl 1):S59-60: S59-S60.
    • (1997) J Endocrinol , vol.155 , Issue.1 SUPPL.
    • Jaquet, P.1
  • 38
    • 0003289231 scopus 로고    scopus 로고
    • A six-week, double blind, placebo controlled study of a growth hormone antagonist, B 2036-PEG (Trovert™), in acromegalic patients
    • June 24-27, New Orleans, Louisiana, USA [OR4-1]
    • van der Lely AJ, Lamberts SW, Barkan A, et al. A six-week, double blind, placebo controlled study of a growth hormone antagonist, B 2036-PEG (Trovert™), in acromegalic patients. The 80th Annual Meeting of the Endocrine Society, 1998 June 24-27, New Orleans, Louisiana, USA [OR4-1].
    • (1998) The 80th Annual Meeting of the Endocrine Society
    • Van Der Lely, A.J.1    Lamberts, S.W.2    Barkan, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.